Biomerica, Inc. (BMRA) |
| 2.3877 -0.042 (-1.74%) 05-29 16:00 |
| Open: | 2.36 |
| High: | 2.4579 |
| Low: | 2.36 |
| Volume: | 6,852 |
| Market Cap: | 7(M) |
| PE Ratio: | -1.48 |
| Exchange: | NASDAQ Capital Market |
| Industry: | Medical - Devices |
| Sector: | Healthcare |
| Technical analysis | ||||
![]() |
||||
| sell | buy | |||
| Resistance 2: | 2.91 |
| Resistance 1: | 2.49 |
| Pivot price: | 2.36 |
| Support 1: | 2.26 |
| Support 2: | 2.11 |
| 52w High: | 4.6 |
| 52w Low: | 1.87 |
Biomerica, Inc., a biomedical technology company, develops, patents, manufactures, and markets diagnostic and therapeutic products for the detection and/or treatment of medical conditions and diseases worldwide. The company's diagnostic test kits are used to analyze blood, urine, or fecal specimens from patients in the diagnosis of various diseases and other medical complications; or to measure the level of specific bacteria, hormones, antibodies, antigens, or other substances, which exist in the patient's body and stools or blood in extremely small concentrations. It primarily sells its products for gastrointestinal diseases, food intolerances, diabetes, and various esoteric tests at the physicians' offices and over-the-counter drugstores, and hospital/clinical laboratories. The company is also developing InFoods, an irritable bowel syndrome therapy technology and diagnostic-guided therapy; Helicobacter pylori products, as well as develops, tests, validates, and sells diagnostic products for COVID-19 infection. Biomerica, Inc. was incorporated in 1971 and is headquartered in Irvine, California.
| EPS | -1.610 |
| Book Value | 1.100 |
| PEG Ratio | 0.00 |
| Gross Profit | 0.061 |
| Profit Margin (%) | -96.46 |
| Operating Margin (%) | -131.51 |
| Return on Assets (ttm) | -54.6 |
| Return on Equity (ttm) | -94.3 |
Thu, 28 May 2026
Biomerica (BMRA) Secures Master Services Agreement for Diagnosti - GuruFocus
Thu, 28 May 2026
Undisclosed $1.75M lab deal taps Biomerica’s diagnostic test expertise - Stock Titan
Tue, 19 May 2026
ConsumerDirect adds new CFO to scale its subscription business - Stock Titan
Fri, 08 May 2026
BMRA | BIOMERICA INC Insider Trading - Quiver Quantitative
Wed, 22 Apr 2026
BMRA (Biomerica Inc.) slips 0.91% following Q1 2026 earnings release with no available analyst consensus estimates. - Hedge Fund Inspired Picks - Xã Thanh Hà
Thu, 16 Apr 2026
Biomerica, Inc. Receives Medicare Confirmation for inFoods® IBS Claims Processing Pathway - Quiver Quantitative
|
StockChart iOS |
StoxlineLite iOS |
StoxlineLite iOS |
OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |